97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details


臨床試験数 : 2,527 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

  
21 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01287195
(ClinicalTrials.gov)
April 7, 201128/1/2011Oral OKT3 for the Treatment of Active Ulcerative ColitisOral Anti-CD3 for the Treatment of Active Ulcerative ColitisUlcerative ColitisDrug: Oral OKT3;Drug: OmeprazoleBrigham and Women's HospitalNULLCompleted18 Years65 YearsAll6Phase 1/Phase 2United States
2EUCTR2005-003707-37-BE
(EUCTR)
25/05/200718/12/2006A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisA Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, IncNULLNot RecruitingFemale: yes
Male: yes
150Phase 3Belgium;Austria
3EUCTR2005-003707-37-AT
(EUCTR)
09/05/200703/01/2007A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisA Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, IncNULLNot RecruitingFemale: yes
Male: yes
150Phase 3Belgium;Austria
4EUCTR2005-003482-17-GB
(EUCTR)
26/02/200701/02/2006A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisA Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
165Phase 2United Kingdom;Spain;Ireland;Italy;Greece
5EUCTR2005-003482-17-GR
(EUCTR)
30/01/200724/11/2006A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ DA Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ D Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 2United Kingdom;Spain;Ireland;Italy;Greece
6EUCTR2005-003481-42-GR
(EUCTR)
30/01/200724/11/2006A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study - RESTORE™ RA Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study - RESTORE™ R Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
80Hungary;Germany;Czech Republic;Slovakia;Spain;Ireland;Italy;Greece
7EUCTR2005-003481-42-ES
(EUCTR)
26/05/200615/03/2006A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab StudyEstudio aleatorizado, doble ciego y multicéntrico de Visilizumab frente a placebo en sujetos con colitis ulcerosa refractaria a esteroides intravenosos que hayan respondido previamente en un estudio con Visilizumab.A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab StudyEstudio aleatorizado, doble ciego y multicéntrico de Visilizumab frente a placebo en sujetos con colitis ulcerosa refractaria a esteroides intravenosos que hayan respondido previamente en un estudio con Visilizumab. Intravenous steroid-refractory ulcerative colitis (IVSR-UC)Colitis ulcerosa refractaria a esteróides intravenonsos
MedDRA version: 8.0;Level: LLT;Classification code 10045265
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Hungary;Germany;Czech Republic;Slovakia;Ireland;Spain;Italy;Greece
8EUCTR2005-003482-17-ES
(EUCTR)
26/05/200615/03/2006A Phase 2, Randomized, Double-blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisEstudio fase 2, aleatorizado, doble ciego, multicéntrico, de exploración de dosis de Visilizumab en sujetos con colitis ulcerosa refractaria a esteróides intravenosos.A Phase 2, Randomized, Double-blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisEstudio fase 2, aleatorizado, doble ciego, multicéntrico, de exploración de dosis de Visilizumab en sujetos con colitis ulcerosa refractaria a esteróides intravenosos. Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
MedDRA version: 8.0;Level: LLT;Classification code 10045265
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 2United Kingdom;Ireland;Spain;Italy;Greece
9EUCTR2005-003481-42-SK
(EUCTR)
21/04/200625/11/2005A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab StudyA Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study Intravenous steroid-refractory ulcerative colitis (IVSR-UC)Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
Protein Design Labs, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 2Czech Republic;Hungary;Slovakia;Greece;Spain;Ireland;Austria;Germany
10EUCTR2005-003481-42-HU
(EUCTR)
04/04/200628/11/2005A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study - RESTORE™ RA Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study - RESTORE™ R Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
80Hungary;Germany;Czech Republic;Slovakia;Spain;Ireland;Italy;Greece
11EUCTR2005-003481-42-IE
(EUCTR)
04/04/200610/01/2006A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab StudyA Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study Intravenous steroid-refractory ulcerative colitis (IVSR-UC)Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, IncNULLNot RecruitingFemale: yes
Male: yes
80Phase 2Czech Republic;Hungary;Slovakia;Greece;Spain;Ireland;Austria;Germany
12EUCTR2005-002063-87-HU
(EUCTR)
04/04/200602/05/2007A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisA Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Intravenous steroid-refractory ulcerative colitis (IVSR-UC)Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
Protein Design Labs, Inc.NULLNot RecruitingFemale: yes
Male: yes
150Phase 2/3Hungary;Germany;Czech Republic;Belgium
13EUCTR2005-002063-87-DE
(EUCTR)
22/03/200629/11/2005A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisA Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, IncNULLNot RecruitingFemale: yes
Male: yes
150Phase 2/3Hungary;Czech Republic;Germany;Belgium
14EUCTR2005-003481-42-DE
(EUCTR)
22/03/200629/11/2005A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study - RESTORE™ RA Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study - RESTORE™ R Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
80Hungary;Czech Republic;Slovakia;Germany;Spain;Ireland;Italy;Greece
15EUCTR2005-002063-87-SK
(EUCTR)
16/03/200623/11/2005A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisA Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, IncNULLNot RecruitingFemale: yes
Male: yes
150Phase 2;Phase 3Hungary;Czech Republic;Slovakia;Belgium;Austria;Germany
16EUCTR2005-003482-17-IE
(EUCTR)
03/03/200610/01/2006A Phase 2, Randomized, Double-blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisA Phase 2, Randomized, Double-blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
MedDRA version: 8.0;Level: LLT;Classification code 10045265
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, Inc.NULLNot RecruitingFemale: yes
Male: yes
100Phase 2Greece;Spain;Ireland;Italy;United Kingdom
17EUCTR2005-003481-42-CZ
(EUCTR)
16/02/200628/11/2005A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study - RESTORE™ RA Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study - RESTORE™ R Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
MedDRA version: 9.0;Level: LLT;Classification code 10045365
Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Hungary;Germany;Slovakia;Czech Republic;Spain;Ireland;Italy;Greece
18EUCTR2005-002063-87-CZ
(EUCTR)
16/02/200628/11/2005A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisA Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Intravenous steroid-refractory ulcerative colitis (IVSR-UC)Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
PDL BioPharma, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150Phase 2/3Hungary;Germany;Czech Republic;Belgium
19EUCTR2005-002063-87-BE
(EUCTR)
09/02/200624/11/2005A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisA Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Intravenous steroid-refractory ulcerative colitis (IVSR-UC)Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
Protein Design Labs, Inc.NULLNot RecruitingFemale: yes
Male: yes
150Phase 2/3Hungary;Germany;Czech Republic;Belgium
20EUCTR2005-003481-42-AT
(EUCTR)
04/01/200630/11/2005A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab StudyA Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study Intravenous steroid-refractory ulcerative colitis (IVSR-UC)Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: Visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
Protein Design Labs, IncNULLNot RecruitingFemale: yes
Male: yes
80Czech Republic;Hungary;Slovakia;Greece;Spain;Ireland;Austria;Germany
21EUCTR2005-002063-87-AT
(EUCTR)
28/12/200523/11/2005A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisA Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Intravenous steroid-refractory ulcerative colitis (IVSR-UC)Product Name: Visilizumab (Nuvion)
Product Code: HuM291
INN or Proposed INN: visilizumab
Other descriptive name: anti-CD3 monoclonal antibody
Protein Design Labs, Inc.NULLNot RecruitingFemale: yes
Male: yes
150Phase 2/3Hungary;Czech Republic;Belgium;Austria;Germany